BMEA
Biomea Fusion Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro
Market Cap: 564 Million
Primary Exchange: NASDAQ
Website: biomeafusion.com
Shares Outstanding: 35.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.592142417658758
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 639 trading days
From: 2021-06-10 To: 2023-03-27
Lowest Point:
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|